Thomas Schmelter Selected Research

Macular Degeneration (Age-Related Maculopathy)

3/2024	Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
1/2024	Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.
1/2023	Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
1/2023	Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.
9/2021	EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.
1/2020	Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.
1/2019	The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Schmelter Research Topics

Disease

11	Macular Edema 01/2023 - 08/2012
7	Macular Degeneration (Age-Related Maculopathy) 03/2024 - 01/2019
4	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2023 - 08/2012
3	Neoplasms (Cancer) 12/2015 - 10/2010
2	Retinopathy of Prematurity (Retrolental Fibroplasia) 04/2024 - 01/2022
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2015 - 06/2013
2	Ovarian Neoplasms (Ovarian Cancer) 01/2013 - 10/2010
1	Retinal Neovascularization 04/2024
1	Retinal Detachment (Retinal Detachments) 04/2024
1	Myopia 04/2024
1	Retinal Diseases 01/2023
1	Polypoidal Choroidal Vasculopathy 05/2021
1	Retinal Vein Occlusion 01/2021
1	Choroidal Neovascularization 01/2019
1	Diarrhea 12/2015
1	Fatigue 12/2015
1	Exanthema (Rash) 12/2015
1	Ovarian Cysts (Ovarian Cyst) 05/2015
1	Hemorrhage 05/2013
1	Metrorrhagia (Spotting) 05/2013
1	Prostatic Neoplasms (Prostate Cancer) 01/2013
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2013
1	Hyperemia 08/2012
1	Heart Failure 08/2012
1	Nausea 08/2012
1	Eye Hemorrhage 08/2012
1	Pain (Aches) 08/2012
1	Hypertension (High Blood Pressure) 08/2012
1	Breast Neoplasms (Breast Cancer) 10/2010

Drug/Important Bio-Agent (IBA)

19	afliberceptIBA 04/2024 - 08/2012
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2024 - 08/2012
3	Epothilones (Epothilone)IBA 06/2013 - 10/2010
3	sagopiloneIBA 06/2013 - 10/2010
2	Retinaldehyde (Retinal)IBA 01/2019 - 08/2012
2	Levonorgestrel (Plan B)FDA LinkGeneric 05/2015 - 05/2013
1	DEAE-Dextran (Pulsar)IBA 03/2024
1	Azure AIBA 01/2024
1	finerenoneIBA 01/2023
1	Angiopoietin-2IBA 01/2023
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2020
1	regorafenibIBA 01/2019
1	Ophthalmic Solutions (Eye Drops)IBA 01/2019
1	ErbB Receptors (EGF Receptor)IBA 12/2015
1	Sorafenib (BAY 43-9006)FDA Link 12/2015
1	Circulating Tumor DNAIBA 12/2015
1	Contraceptive Agents (Contraceptives)IBA 05/2015
1	Tranexamic Acid (AMCA)FDA Link 05/2013
1	Mefenamic Acid (Pontal)FDA Link 05/2013
1	Acetylcarnitine (Alcar)IBA 01/2013
1	PlatinumIBA 10/2010

Therapy/Procedure

7	Lasers (Laser) 04/2024 - 08/2012
5	Light Coagulation 01/2022 - 08/2012
2	Therapeutics 02/2017 - 06/2013
1	Injections 04/2024
1	Laser Therapy (Surgery, Laser) 04/2024
1	Photochemotherapy (Photodynamic Therapy) 05/2021
1	Castration 01/2013
1	Drug Therapy (Chemotherapy) 10/2010